Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30321179 | 1.00 | LMNA (0.42) | LMNARIPK3PTGS2MAPK14PTGDR2 | |
| SCHEMBL30321290 | 0.92 | AGTR1 (0.44) | LMNAPTGDR2ALDH3A1GBA1 | |
| SCHEMBL26969367 | 0.85 | LMNA (0.43) | LMNAPTGDR2ALDH3A1HTR6 | |
| SCHEMBL20575807 | 0.80 | MAPK14 (0.39) | LMNARIPK3PTGS2MAPK14PTGDR2 | |
| SCHEMBL30321193 | 0.80 | MAPK14 (0.39) | LMNARIPK3PTGS2MAPK14PTGDR2 | |
| SCHEMBL29604791 | 0.75 | CA1 (0.46) | LMNAPTGDR2ALDH3A1HTR6 | |
| SCHEMBL14685251 | 0.75 | CA1 (0.46) | LMNAPTGDR2ALDH3A1HTR6 | |
| SCHEMBL29604690 | 0.73 | PTGDR2 (0.46) | LMNAPTGDR2ALDH3A1 | |
| SCHEMBL20576447 | 0.73 | AGTR1 (0.39) | LMNAMAPK14PTGDR2ALDH3A1HTR6 | |
| SCHEMBL29605389 | 0.73 | PTGDR2 (0.41) | LMNAPTGDR2ALDH3A1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362451-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-20200299294-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-24 | — | — | US | disclosed |
| US-10717732-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-20180346463-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299294-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | LMNA 1193/4885RIPK3 3580/4885PTGS2 2513/4885 |
| US-20180346463-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | LMNA 1193/4885RIPK3 3580/4885PTGS2 2513/4885 |
| US-10717732-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | POLRMT, EIF2AK2, POLM | LMNA 1193/4885RIPK3 3580/4885PTGS2 2513/4885 |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | POLRMT, EIF2AK2, POLM | LMNA 1193/4885RIPK3 3580/4885PTGS2 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.